Overview
- Sanofi reported phase 2 wins for lunsekimig in asthma and nasal polyps, a bispecific drug that blocks TSLP and IL‑13.
- In the AIRCULES phase 2b asthma trial, the drug cut flare‑ups and improved lung function measured by pre‑bronchodilator FEV1.
- In the DUET phase 2a sinusitis trial, it reduced polyp size and improved nasal congestion and CT scan scores by Week 24.
- An exploratory atopic dermatitis study missed its main goal yet showed higher skin‑clearance rates on secondary measures.
- The company described an overall tolerability profile close to placebo and said larger studies and detailed readouts are next.